{"entity":{"id":"nct07130903","kind":"trial","name":"Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer","aka":[],"tldr":"A phase 2 trial of fruquintinib in colorectal cancer, run by Barbara Ann Karmanos Cancer Institute, now recruiting.","summary":"Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer is a phase 2, interventional study registered as NCT07130903 by Barbara Ann Karmanos Cancer Institute, with a registry enrolment figure of 102 participants, started 2025-09-10 and due to reach its primary completion in 2028-04-17. Interventions recorded: Fruquintinib; TheraBionic P1. Conditions listed: Metastatic Colorectal Adenocarcinoma. Primary outcome: Overall Survival (OS). Colorectal eligibility wording from the registry: \"* Participant must have histologically or cytologically confirmed metastatic colorectal adenocarcinoma\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07130903","url":"https://clinicaltrials.gov/study/NCT07130903"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["antiangiogenic","kinase-inhibitors","thermal-ablation"],"targets":[],"drugs":["fruquintinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07130903","phase":"2","setting":"A Phase 2 Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer","sponsor":"Barbara Ann Karmanos Cancer Institute","enrolled":102,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07130903/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"},{"id":"thermal-ablation","kind":"technology","name":"Thermal ablation (RFA, microwave, cryo)","route":"/technologies/thermal-ablation/"}],"drug":[{"id":"fruquintinib","kind":"drug","name":"Fruquintinib","route":"/drugs/fruquintinib/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}